Stockreport

Intellia Stock Declines Around 55% in 3 Months: Here's Why [Yahoo! Finance]

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF to nexiguran ziclumeran (nex-z), NTLA's lead pipeline candidate. It is being developed in collaboration with Regeneron Pharmaceuticals REGN for the treatment of ATTR amy [Read more]